Felpreva™ (emodepside, praziquantel, and tigolaner topical solution) receives FDA approval, offering cats parasite protection with just 4 applications a year*
FORT WORTH, TEXAS (Nov. 16, 2026) – Vetoquinol USA, Inc., announces that Felpreva™ (emodepside, praziquantel, and tigolaner topical solution) received approval from the U.S. Food & Drug Administration (FDA). Felpreva is:
- A safe and effective broad‑spectrum parasiticide designed specifically for cats
- Applied just four times a year* in an easy, topical dose — meaning fewer applications and less stress for cats and their owners
- Certified Easy to Give™ Approved by International Cat Care (ICC)
In a survey, up to 48% of cat owners said they do not follow year-round parasite prevention recommendations.1 Less frequent administration — combined with feline-friendly topical administration — helps take the complexity out of parasite control for both veterinarians and cat owners.
“We are excited to bring Felpreva to U.S. veterinarians and cat owners,” said Michael Maginnis, Country Manager, Vetoquinol USA. “Felpreva takes the complexity out of parasite control for both veterinarians and cat owners by providing a straightforward solution: Fewer applications with broad-spectrum treatment and control.”
Felpreva is a prescription-only product that combines three active ingredients: emodepside to treat roundworms; praziquantel to treat tapeworms; and tigolaner to control fleas, ticks, and mites.
Approved for use in the European Union in 2022, the combination of active ingredients in Felpreva has been trusted by veterinarians and cat owners across the EU with millions of doses sold. Last year, Felpreva was the leading feline parasiticide choice in both the United Kingdom and France.1
Veterinarians will be able to order Felpreva through distributors in 2027. Visit vetoquinolusa.com/felpreva to learn more about Felpreva.
* Treats and prevents fleas and treats and controls black-legged ticks for 12 weeks; treats and controls lone star ticks for 8 weeks.
IMPORTANT SAFETY INFORMATION:
FELPREVA (emodepside, praziquantel, and tigolaner topical solution) is only for topical use in cats and kittens 6 months of age and older weighing at least 2.2 lbs. The most commonly reported adverse reactions include vomiting, lethargy, pruritus, hair changes, and application site reaction. Avoid oral ingestion or exposure. Use with caution in sick or debilitated, heartworm positive, and/or in cats with a history of neurologic disorders. Safety has not been established in breeding, pregnant, or lactating cats. Children and pregnant women should not come in contact with the application site for twenty four (24) hours. Tigolaner, an ingredient in FELPREVA, is a bispyrazole, which is similar to the isoxazoline class. Isoxazoline drugs have been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Neurologic adverse reactions have been reported in cats with or without a history of neurologic disorders. For full prescribing information, visit www.vetoquinolusa.com/felpreva-info.
Company Contact Information
Consumers:
Vetoquinol USA Account Services
800-267-5707
customerserviceusa@vetoquinol.com
For media requests:
About Vetoquinol USA
Headquartered in Fort Worth, Texas, Vetoquinol USA, Inc. is owned by Vetoquinol S.A., an independent, family-owned French pharmaceutical company founded in 1933. Dedicated exclusively to animal health, Vetoquinol USA is focused on the development, production, and marketing of AAFCO, NASC, EPA, and FDA-regulated pharmaceutical, nutritional, and dermatological products for small and large animals.
1. Data on file.
©2026 VETOQUINOL USA, Inc. VETOQUINOL and FELPREVA are trademarks of VETOQUINOL. FEL-26-00027.
Latest news
Vetoquinol Launches Pet Owner Rebate Program in Partnership with ACB
October 2026
August 2026
New World screwworm emphasizes importance of fast wound healing
July 2026